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Abstract
U.S. military personnel assigned to areas deemed to be at high risk for anthrax attack receive 
Anthrax Vaccine Adsorbed (AVA). Few cases of rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) have been reported in persons who received AVA. Using a matched case–
control study design, we assessed the relationship of RA and SLE with AVA vaccination using the 
Defense Medical Surveillance System. We identified potential cases using International 
Classification of Diseases, 9th Revision, Clinical Modification codes and confirmed cases with 
medical record review and rheumatologist adjudication. Using conditional logistic regression, we 
estimated odds ratios (OR) for AVA exposure during time intervals ranging from 90 to 1,095 days 
before disease onset. Among 77 RA cases, 13 (17%) had ever received AVA. RA cases were no 
more likely than controls to have received AVA when looking back 1,095 days (OR: 1.03; 95% 
confidence interval [CI]: 0.48–2.19) but had greater odds of exposure in the prior 90 days (OR: 
3.93; 95% CI: 1.08–14.27). Among the 39 SLE cases, 5 (13%) had ever received AvA; no 
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significant difference in receipt of AVA was found when compared with controls (OR: 0.91; 95% 
CI: 0.26–3.25). AVA was associated with recent onset RA, but did not increase the risk of 
developing RA in the long term.
INTRODUCTION
Anthrax is an infectious disease caused by the bacterium Bacillus anthracis, which can be 
used as a bioweapon. Anthrax Vaccine Adsorbed (AVA) was licensed in the United States in 
1970 for the prevention of anthrax. The first large-scale use of AVA was in 1991 for U.S. 
military personnel deployed during the Persian Gulf War. In 1998, the U.S. military started 
the Anthrax Vaccine Immunization Program to protect U.S. military active duty and reserve 
members as well as emergency-essential civilians assigned to areas deemed to be at high risk 
for anthrax attack.1 From March 1998 through September 2005, nearly 5.6 million doses of 
AVA were administered to 1.5 million U.S. military personnel.2 Service member and public 
concerns about the safety of AVA led to epidemiologic studies of the association of AVA 
with various medical conditions, yet no increased risks have been identified.2 One concern 
was about arthralgia following vaccination, and in particular, 1 case of rheumatoid arthritis 
(RA) and 2 cases of systemic lupus erythematosus (SLE) were reported in U.S. military 
personnel.3,4
RA and SLE are chronic inflammatory autoimmune diseases that share some clinical and 
laboratory features along with the other connective tissue diseases. The exact etiology of 
these diseases is unknown, though they are believed to result from a complex interplay of 
genetic, environmental, and hormonal factors. Various infectious and noninfectious 
environmental exposures have been proposed as possible triggers of the disease process, 
including vaccines. Case reports of new-onset RA and SLE following receipt of various 
types of vaccines date back to the 1940s.3–9 Reports have involved hepatitis B (hep B),8,9 
influenza,7 rubella,6 tetanus,10 rabies,10 and anthrax vaccines,4 though no association has 
been confirmed in population-based epidemiologic studies to date.11
In response to the case reports of RA and SLE following AVA in military personnel, the 
objective of our study was to assess the relationship between those two diseases following 
vaccination with AVA. RA and SLE are both diffuse connective tissue diseases that share 
some similar features but are distinct and occur with different epidemiology, and therefore 
are examined separately.
METHODS
Study Population and Design
The study population was drawn from the Defense Medical Surveillance System (DMSS) 
database. The DMSS is a longitudinal surveillance database with current and historical data 
for military personnel since 1990.12 DMSS continuously captures a range of information 
including immunizations, inpatient and outpatient medical conditions coded using the 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), 
demographic characteristics, military personnel data, and deployment-related information. 
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Medical encounter data are most comprehensive for active duty personnel. We performed a 
case–control study, and selected subjects from military personnel who were on active duty at 
any time during the period from January 1, 1998 through December 31, 2005.
Case Identification, Validation, and Classification
Case identification involved the following steps: (1) identification of all personnel with a 
first time ICD-9-CM code for RA or SLE in any inpatient or outpatient setting in the 
electronic database (including codes for RA and RA variants: 714.0, 714.1, 714.2, 714.81, 
and the code for SLE: 710.0); (2) review of the preselected individual’s chart, if available at 
either the National Personnel Records Center, St. Louis, Missouri, or the respective Military 
Treatment Facility (MTF); (3) medical record abstraction to obtain clinical, laboratory, and 
radiology information; and (4) medical record review and case adjudication by 
rheumatologist clinical reviewers (JBH, MPK, PJP, and WRG). Medical records were 
abstracted up to 3 years before the date of diagnosis or back to the enlistment date for those 
enlisted <3 years, and up to 1 year following the date of diagnosis.
The de-identified disease-specific abstracted information was provided to the rheumatologist 
clinical reviewers to validate and classify the cases according to the 1987 revised American 
Rheumatology Association (ARA) criteria for the classification of RA and the modification 
to the 1982 revised criteria for the classification of SLE.13–15 Cases were classified as 
“probable—fulfills criteria,” “probable—does not fulfill criteria,” or “unconfirmable” 
according to the case definitions in Table I. Cases were classified as “probable—does not 
fulfill criteria” when the patient had an established diagnosis of the disease in the medical 
record, but the documentation available for abstraction was either not complete or did not 
include a statement of all the specific criteria present. If the two primary reviewers disagreed 
on the diagnosis, the case was reviewed by a third reviewer. The clinical reviewers were 
blinded to the vaccination status of the subjects. Only the cases classified as “probable—
fulfills criteria” or “probable—does not fulfill criteria” were included in our analyses.
The clinical reviewers identified the cases’ disease onset date based on the medical record 
abstraction information. This date was used as the index date for the study. Controls were 
randomly selected from among active duty military personnel who never had any of the 
ICD-9-CM codes recorded in the DMSS for RA, SLE, other diffuse connective tissue 
diseases, or other conditions or symptoms that could represent early undiagnosed forms of 
these diseases (ICD9 codes in Tables AI and AII of the Appendix). Each case was 
individually matched to three controls on sex, age, service branch, and calendar time of 
beginning under medical surveillance. For one case, only one matched control could be 
identified.
Vaccine Exposure
History of vaccination with AVA and other vaccines during military service was retrieved 
from the DMSS. During our study period, the originally licensed AVA administration 
schedule was followed, consisting of a 6-dose priming series of 0.5-mL subcutaneous 
injections given at 0, 2, and 4 weeks, and 6, 12, and 18 months followed by annual boosters 
thereafter. A biologically plausible time interval from a putative environmental exposure 
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(i.e., vaccine) to the onset of RA or SLE is not known, so we examined exposure to AVA 
during exposure intervals previously used to assess RA following vaccinations.16 Because 
AVA is given as a multidose series and risk could potentially be related to the number of 
doses received, we also assessed the number of doses received in each exposure interval as 
well as the total number of doses received before the index date. In addition, we compared 
those who had received at least 3 doses of the priming series with those who had not.
Statistical Analysis
We used conditional logistic regression models to estimate the matched odds ratio (mOR) 
comparing the odds of the cases having been vaccinated to the odds of vaccination in the 
controls. RA and SLE were analyzed separately. Confounding variables were identified 
using directed acyclic graphs. In addition to sex, age, and service branch, which were 
controlled for via matching, deployment status was also a confounder and was included in 
the multivariable models. We attempted to assess effect measure modification between AVA 
and the other types of vaccines previously speculated to be associated with RA (inactivated 
influenza vaccine, measles–mumps–rubella combination vaccine [MMR], hep B vaccine, 
tetanus–diphtheria vaccine [Td], or tetanus–toxoid [TT] vaccine), but the number of 
individuals exposed to the various combinations of these vaccines during the same exposure 
intervals as AVA was low and did not provide adequate statistical power (data not shown). 
We performed the analysis using SAS software version 9.3 (SAS Institute Inc., Cary, North 
Carolina).
RESULTS
In the DMSS database, we identified 5,049 individuals with one of the RA ICD 9-CM codes 
and 1,646 with the SLE code, including 23 with codes for both diseases. Medical record 
abstraction was completed for 211 patients whose adjudicated case classification was: RA (n 
= 133), SLE (n = 81), both RA and SLE (n = 3). Among these, 77 were determined to be 
“probable” RA cases (92.2% fulfilled criteria) and were matched to 229 controls, and 39 
were determined to be “probable” SLE cases (71.8% fulfilled criteria) and were matched to 
117 controls (Table II). One individual was determined to be a “probable” case of both RA 
and SLE. The final study population size was dependent on the resources available for case 
medical record abstraction, which resulted in a number of cases below the goal size of 260 
“probable” cases for each disease that had been calculated a priori to be needed to achieve a 
statistical power ≥80% to detect an OR of ≥1.6. Our sample was sufficiently powered (80%) 
to detect an OR > 2.2 for RA and an OR > 3.1 for SLE.
The majority of RA cases were men (67.5%), whereas the majority of SLE cases were 
women (71.8%). RA cases were somewhat evenly distributed by age at onset, with the 
largest portion in the 25- to 34-year-old range (38.9%), whereas the age at onset for SLE 
cases tended to be younger, with most in the 18- to 24- year-old range (53.8%). RA cases 
were most frequently non-Hispanic white (68.8%), whereas SLE cases were most frequently 
non-Hispanic black (43.6%).
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RA Analysis
Compared with controls, fewer individuals with RA ever received a dose of AVA during 
their military service before the index date (16.9% vs. 22.3%; Table II). The number of days 
between receipt of the most recent dose of AVA and the index date was shorter for the RA 
cases (median 55 [interquartile range: 21–258; range: 5–1,753]) than for controls (median 
380 [interquartile range: 141–908; range: 7–2,030]). When examining the odds of having 
received AVA during each specified exposure interval, we found cases were more often 
exposed to AVA within the 90 days before the index date than were controls (mOR: 3.93; 
95% confidence interval [CI]: 1.08–14.27; Table III). As the length of the exposure interval 
increased, the OR for AVA exposure consistently decreased from 2.21 (95% CI: 0.75–6.52) 
for the 180-day interval to 1.03 (95% CI: 0.48–2.19) for the 1,095-day interval. Only the 
result for the 90-day interval was statistically significant, and the power to detect the OR of 
3.93 was determined post hoc to be 99%. Among the 7 cases vaccinated during the 90-day 
exposure interval, 6 only received 1 dose during that interval but it was after the first 3 doses 
of the priming series for 5 of them (fourth dose, n =1; fifth dose, n = 2; sixth dose, n =1; 
seventh dose, n = 1). One case received the first 3 doses of the AVA priming series during 
the 90-day interval, compared with 3 of the 8 controls. Half of the 8 controls received only 1 
AVA dose during the 90-day exposure interval (first dose, n = 1; second dose, n =1; fourth 
dose, n = 2). One control received the second and third AVA priming doses during the 90-
day exposure interval.
When assessing the number of AVA doses received during each of the five exposure 
intervals, we found no significant difference between cases and controls (Table III and Fig. 
1). When comparing the total number of AVA doses ever received vs. receiving no doses of 
AVA, we found no significant differences between cases and controls for any number of 
doses from 1 through 7 (Table III). Cases were less likely than controls to have received 3 or 
more doses compared to less than 3 doses (OR: 0.56; 95% CI: 0.25–1.25) though this was 
not statistically significant. In addition, among those who had received at least 3 AVA doses, 
the difference was not significant between cases and controls in the median number of days 
from receiving the first dose of AVA and the index date (cases: 787 days vs. controls: 817 
days, p = 0.83).
SLE Analysis
Among the 39 SLE cases, 5 (12.8%) had ever received a dose of AVA compared with 19 
(16.2%) of the 117 controls. Because of the small sample size for the SLE analysis, we were 
unable to assess the OR for each exposure interval. However, we did look at the odds of ever 
having received AVA, adjusting for deployment status, and found no association (mOR: 
0.91; 95% CI: 0.26–3.25). The mean number of total AVA doses ever received before the 
index date was slightly lower among cases, but not significantly different from the controls 
(Table II). The number of days between receipt of the most recent dose of AVA and the 
index date was longer for SLE cases (median 1,001 [interquartile range: 593–1,968; range: 
577–2,115]) than for controls (median: 243 [interquartile range: 113– 604; range: 14–
2,074]).
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DISCUSSION
In this case–control study, we found no association between RA and SLE and having ever 
received AVA, or with the number of doses of AVA received. Moreover, those diagnosed 
with RA or SLE were less frequently exposed to AVA than their matched controls and 
received fewer total doses of AVA before the onset of their disease. Yet, we identified an 
increased risk of new-onset RA associated with having received AVA within 90 days before 
disease onset. The majority of cases (71%) who received AVA within the 90 days before 
disease onset received more than the first 3 doses of priming series (i.e., fourth to seventh 
dose), whereas only 2 (25%) of the controls received a fourth dose of the priming series. As 
the vaccine exposure interval increased from 90 days up to the longest exposure interval we 
examined of 1,095 days, the OR consistently trended down toward 1, indicating no 
difference in risk over the longer term for those persons who received AVA. This pattern 
suggests that exposure to AVA might hasten the onset of RA in some individuals, but 
eventually, those individuals would have developed RA as a result of exposure to other 
factors, regardless of receipt of AVA.
In the general population, the incidence of RA has been estimated to be 300 to 500 per 1 
million persons per year, whereas for SLE, it is 25 to 100 per 1 million person-years.17 In 
the military population represented in the DMSS database, we found a larger number of 
persons with an RA diagnosis code than with an SLE diagnosis code as expected. We also 
observed a difference in age distribution of disease onset between RA and SLE cases in our 
adjudicated study population, which was expected because the incidence of RA increases 
with age, peaking at 75 to 84 years old, whereas SLE incidence peaks in middle age.18,19 In 
the general population, RA has a slight female predominance (2:1), whereas SLE has a 
strong female predominance (9:1).19,20 In our study population, which was derived from the 
U.S. military population which is majority male, most of the RA cases occurred in males 
and most SLE cases occurred in females, which is consistent with what would be expected 
based on the differences in the sex-specific incidence rates between the two diseases in the 
general population. Although the military population does not resemble the age and sex 
distribution of the general population, our study population is representative of persons who 
are most likely to receive the AVA vaccine, as the vast majority of AVA administered in the 
United States is given to military personnel.
As with other autoimmune diseases, certain genes in the HLA complex have been associated 
with increased or decreased risk of developing the diffuse connective tissue diseases, disease 
severity, response to pharmacological therapy, and prognosis. The specific haplotypes and 
subhaplo-types conferring risk or protection appear to vary by disease; however, no single 
gene completely accounts for increased genetic risk as multiple genes are likely involved.
21,22
 Among persons genetically susceptible to developing RA, it is believed an external 
factor is needed to trigger disease onset. It is unlikely that all cases can be attributed to a 
single type of trigger; rather it is probable that a number of agents are capable of triggering 
the autoimmune process.22 In a person genetically predisposed to developing RA, avoidance 
of one trigger would not preclude exposure to a different trigger initiating the disease 
process at a later date. Therefore, evaluating the risk of disease over longer follow-up 
periods would tend to obscure the effects of an individual exposure with shortterm risk, such 
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as a vaccine exposure, but provide a better estimate of the overall contribution of that 
exposure to the cumulative risk of developing the disease. It may be that a possible short-
term risk of RA being triggered within the 90 days following exposure to AVA is balanced 
over the longer time period by the risk of RA due to other triggers. Confirmed triggers for 
RA are still unknown, so whether there are any triggers that could be avoided or mitigated to 
prevent RA onset is also unknown. There would appear to be no long-term benefit to avoid 
exposure to AVA vaccine in regard to the development of RA because the short-term risk 
associated with AVA is balanced out by other sources of risk within 2 to 3 years.
In our SLE analysis, we found no risk associated with having ever been exposed to AVA, but 
due to the small number of cases and controls exposed to AVA vaccine, we were unable to 
examine multiple exposure intervals. Therefore, we could not determine if there was a 
pattern of short-term risk similar to that seen with RA, but the lack of long-term risk is 
reassuring and argues against AVA as an influential cause of SLE at the population level.
Two broad screening studies have been conducted to assess potential adverse events 
following AVA in U.S. military personnel, one conducted using the DMSS and one using 
DoD’s Ambulatory Data System, neither of which identified any significant safety concerns.
23,24
 Our study is the first specifically designed to examine the risk of RA or SLE associated 
with AVA, though other studies have previously examined the risk of these diseases in 
relation to other types of vaccines. A Swedish case–control study of incident cases of RA 
found no increased risk of RA within 5 years following immunization with influenza, 
tetanus, diphtheria, hep A or B, polio, or pneumococcal vaccines.11 A population-based 
case–control study in the United Kingdom found no increase in risk of RA within 3 months 
or greater than 3 months after hep B vaccine.25 In addition, a cohort study of Northern 
California Kaiser Permanente health plan members found nonstatistically significant 
elevated relative risks for RA for exposure intervals (90, 180, 365, and 730 days) following 
hep B and tetanus vaccines; receipt of influenza vaccine within an interval of 6 or 12 months 
was associated with a statistically significantly increased risk of RA in a cohort analysis but 
not a case–control design.16 A separate retrospective cohort study from the same health plan 
found no statistically significant risk of developing RA within 1 year of receipt of rubella 
vaccination in immunized women 15 to 59 years old.26 A population-based study of SLE in 
the United Kingdom found no statistically significant association between risk of SLE 
within 12 months of receipt of hep B vaccine in the full sample, but did observe an elevated 
risk among a subset of persons older than 40 years (relative risk = 2.6, 95% CI: 1.1–6.0).27 
Though most studies have not found a risk of new-onset RA associated with other vaccines, 
some analyses indicate a potential low-level risk with other types of vaccines similar to the 
magnitude of short-term risk we observed with AVA. Our study was focused on examining 
the risk with AVA, and while not designed to examine the risk with other vaccines, we did 
not observe an increased risk of RA or SLE with ever having received hep B vaccine, Td/TT 
vaccine, inactivated influenza vaccine, or MMR vaccine (data not shown), which have 
previously been suggested as having a possible association with RA or SLE.
The main limitation of our study was a relatively small sample size. Though the OR for the 
association of RA with AVA during the 90-day interval of 3.93 (95% CI: 1.08–14.27) was 
statistically significant, the wide CI indicates uncertainty in the magnitude of the risk. 
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Unfortunately, we were unable to review charts for all potential cases in the DMSS 
population during the study period due to limited resources, which constrained our sample 
size and thus lowered statistical power. The sample size for the SLE analysis was smaller 
than the RA analysis due to the fact that SLE is a less common disease.
We used the 1987 ARA classification criteria, which were current during the entire study 
period, including the study’s initiation.13 Since then, the 2010 American College of 
Rheumatologists/European League Against Rheumatism Collaborative Initiative RA criteria 
were released, which were meant to improve on the sensitivity of the 1987 ARA criteria for 
detecting early forms of the disease (i.e., classification rules that applied to newly presenting 
patients with undifferentiated synovitis would (1) identify the subset at high risk of 
chronicity and erosive damage, (2) be used as a basis for initiating disease-modifying 
therapy, and (3) not exclude the capture of patients later in the disease course).28 With the 
emphasis being the identification of early vs. established RA, no difference in the risk 
profile of cases would be expected and this would not affect our study since we used the 
case–control design, which does not depend on detection of all possible cases in a 
population. In addition, our study erred on the side of sensitivity by including the cases 
classified as “probable—does not fulfill criteria.” Medical record review and adjudication by 
a team of rheumatologists was an important strength of this study, which helped to avoid 
potential bias from misdiagnosis of cases or misclassification of vaccine exposure as it 
relates to time of disease onset.
We studied a time period during which the original AVA dosing and administration 
recommendations were in effect. In 2008, the Food and Drug Administration approved 
reducing the number of doses for the pre-exposure series from 6 doses to 5 doses and 
changing the route of administration from subcutaneous to intramuscular; the Advisory 
Committee on Immunization Practices published updated recommendations including these 
changes in 2010.29 Whether this new schedule would have the same pattern of association 
with RA or SLE that we have observed in this study is unknown. Differences would not be 
anticipated, however, because in a randomized clinical trial, the new schedule was shown to 
induce a noninferior protective immune response and had similar rates of systemic adverse 
events and lower rates of injection site adverse events in comparison to the original schedule 
at both 7 and 43 months of follow-up.30,31
In conclusion, in this study, we observed an increased risk of new-onset RA associated with 
receipt of AVA when looking back 90 days, but no long-term risk for either RA or SLE 
when looking back up to 3 years. Although our observations suggest that AVA might be a 
potential trigger for RA disease onset, additional studies would be needed, including 
assessing possible biological mechanisms, such as a specific autoimmune pathway that can 
be triggered by epitopes present in the vaccine, before this hypothesis could be confirmed.
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APPENDIX
TABLE AI.
ICD-9-CM Codes Used to Identify Potential Cases of RA or SLE
710.0 Systemic Lupus Erythematosus
714.0 Rheumatoid Arthritis
714.1 Felty’s Syndrome
714.2 Rheumatoid Arthritis With Visceral or Systemic Involvement
714.81 Rheumatoid Lung
TABLE AII.
ICD-9-CM Codes Used to Exclude Patients From the Pool of Potential Control Subjects
17 Tuberculosis of other organs
135 Sarcoidosis
283.0 Autoimmune hemolytic anemia
283.9 Acquired hemolytic anemia, unspecified
286.5 Coagulation disorder due to circulating anticoagulants
286.5 Hemorrhagic disorder due to circulating anticoagulants
287.3 Primary thrombocytopenia
287.4 Secondary thrombocytopenia
287.5 Thrombocytopenia, unspecified
288.0 Agranulocytosis
293 Transient organic psychotic conditions
325 Phlebitis and thrombophlebitis of intracranial venous sinuses
345 Epilepsy
357.1 Polyneuropathy in collagen vascular disease
359.6 Symptomatic inflammatory myopathy in diseases classified elsewhere
359.9 Myopathy, unspecified
370.33 Keratoconjunctivitis sicca
373.34 Discoid lupus erythematosus of the eyelid
375.15 Tear film insufficiency
403 Hypertensive renal disease
420 Acute pericarditis
422 Acute myocarditis
423 Other diseases of the pericardium
424.9 Endocarditis, valve unspecified
429.0 Myocarditis, unspecified
443.0 Raynaud’s syndrome/phenomenon
444 Arterial embolism and thrombosis
451 Phlebitis and thrombophlebitis
453 Other venous embolism and thrombosis
511 Pleurisy
515 Postinflammatory pulmonary fibrosis
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516.3 Idiopathic fibrosing alveolitis
517 Lung involvement in conditions classified elsewhere
517.2 Lung involvement in systemic sclerosis
517.8 Pulmonary involvement in others
527.1 Hypertrophy of salivary glands
527.2 Sialoadenitis
527.7 Disturbance of salivary secretion
528 Diseases of the oral soft tissue
529 Diseases and other conditions of the tongue
530.0 Achalasia and cardiospasm
580 Acute glomerulonephritis
581 Nephrotic syndrome
582 Chronic glomerulonephritis
583 Nephritis and nephropathy not specified as acute or chronic
584 Acute renal failure
585 Chronic renal failure
586 Renal failure and unspecified
587 Pulmonary congestion and hypostasis
587 Renal sclerosis and unspecified
588 Disorders resulting from impaired renal function
599.7 Hematuria
646.2 Unspecified renal disease in pregnancy without mention of hypertension
692.79 Other dermatitis due to solar radiation
695.4 Lupus erythematosus
701.0 Circumscribed scleroderma
704.0 Alopecia
710.0 Systemic lupus erythematosus
710.1 Systemic sclerosis
710.2 Sicca syndrome (Sjogren’s)
710.3 Dermatomyositis
710.4 Polymyositis
710.8 Other specified diseases of connective tissue
710.9 Unspecified diffuse connective tissue disease
714.0 Rheumatoid arthritis
714.1 Felty’s syndrome
714.2 Rheumatoid arthritis with visceral or systemic involvement
714.81 Rheumatoid lung
714.89 Other specified inflammatory arthropathies
714.3 Juvenile chronic polyarthritis
716.5 Unspecified polyarthropathy or polyarthritis
716.8 Other specified arthropathy
716.9 Arthropathy, unspecified
719.0 Effusion of joint-specific sites (includes “joint swelling”)
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719.4 Pain in joint (arthralgia)
719.5 Stiffness of joint, not elsewhere classified
729.0 Rheumatism, unspecified and fibrositis
729.1 Myalgia and myositis, unspecified
780.3 Convulsions
782.8 Changes in skin texture
786.52 Painful respiration
791.0 Proteinuria
794.17 Abnormal electromyography
795.6 False positive serology test for syphilis
V42.0 Kidney transplant
V45.1 Postsurgical states, renal dialysis status
V56 Encounter for dialysis and dialysis catheter care
V82.1 Special screening for rheumatoid arthritis
V82.2 Special screening for other rheumatic disorders
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FIGURE 1. 
RA analysis: box plot of the number of AVA doses received during each exposure interval 
(median, interquartile range, and range) for cases and controls. The horizontal line in the 
middle of the box plot is the median. The circle is the mean. The length of the box 
represents the interquartile range (distance between the 25th and 75th percentiles). The 
vertical lines (called whiskers) issuing from the box extend to the group minimum and 
maximum values.
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